Introduction
Recent developments in stem cell biology have revealed the existence of cancer stem cells (CSCs) in various cancers, including leukemia, breast cancer, and colon cancer. (1) (2) (3) (4) (5) (6) CSCs are a subset of cells with the ability to self-renew, generate a heterogeneous population of cancer cells, and initiate tumor formations. (7, 8) These stem-cell-like features of CSCs contribute to rapid tumor growth, tumor resistance to chemotherapy/radiotherapy, and the epithelial-mesenchymal transition (EMT). (9) (10) (11) Therefore, CSCs have been attracting increasing attention as a new target for cancer therapies.
Liver cancer, including hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths worldwide. Although various therapies have been established and many others are under development, the prognosis of HCC is still poor. In HCC, epithelial cell adhesion molecule (EpCAM), cluster of differentiation (CD) 90, CD133, and sal-like protein 4 have been reported to be useful as CSC surface markers. (12) (13) (14) (15) (16) However, molecular therapeutic targets for HCC-CSCs remain unestablished. During normal hepatic development, hepatic progenitor cells express both the hepatocyte marker albumin and the cholangiocyte marker keratin 19 (K19) . (17, 18) K19 is known to be a marker of poor prognosis in HCC in several studies. (19) (20) (21) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 reported as a key player in tumor invasion in HCC. (22) However, the relationship between K19 and HCC-CSCs is not fully understood. Therefore, based on the similarity between normal tissue stem cells and CSCs, we hypothesized that K19 + cells possess CSC characteristics and that K19 is a therapeutic target in HCC.
The aims of this study were to demonstrate that K19 + cells have CSC properties in HCC, and to investigate whether K19 + cells could be a new therapeutic target. In this study, a transgene vector that expressed green fluorescence protein (EGFP) under the control of the human K19 promoter was transfected into four HCC cell lines to characterize K19 + cells as HCC-CSCs. Using fluorescence-activated cell sorting (FACS)-isolated K19 + /K19 − cells, we explored the relationship between K19 and known HCC-CSC markers, the involvement of K19 + cells in transforming growth factor beta (TGFb)/Smad signaling and EMT, and the therapeutic potential of a TGFb receptor 1 (TGFbR1) inhibitor. Moreover, the expression of K19 and TGFbR1 was investigated in human HCC surgical specimens.
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Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 Thirty-four patients fulfilled the Milan criteria for transplantation, and 28 did not. The clinicopathological characteristics of the subjects are summarized in Supplemental Table 1 . Tumor recurrence was investigated until the patient's death or the end of this study (March 31, 2013) . No patient was lost to follow-up. The follow-up period from surgery until death or the endpoint of this study was 58 to 2808 days (mean 1581 days) in resection group and 223 to 2857 days (mean 1915 days) in transplantation group.
Written informed consent for the use of resected tissue samples was obtained from all patients in accordance with the Declaration of Helsinki, and this study was approved by the institutional review committee of our hospital.
Construction of the transgene vector
We generated a transgene plasmid vector that expressed EGFP under the control of the human K19 promoter. The promoter activity of the 2952-bp 5′-flanking region of the human K19 gene (from −2952bp to the first ATG) was previously reported. (23 DOI: 10.1158 /1078 -0432.CCR-14-1936 plasmid vector pHCK-2952, in which the 2952-bp 5′-flanking region of the human K19 gene was inserted into the pGL3-Basic (Promega, Madison, WI, USA) vector, was kindly provided by Professor Shuichi Kaneko (Kanazawa University, Kanazawa, Japan). (23) We obtained the human K19 promoter region from pHCK-2952 by using XhoI and HindIII (Takara Bio, Otsu, Japan), and we then ligated it with XhoI and HindIII-digested plasmid EGFP-1 (pEGFP1; BD Biosciences, Franklin Lakes, NJ, USA).
Generation of transgenic HCC cell lines
The human HCC cell lines (Huh7, HLF, PLC/PRF/5, and Hep3B) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were authenticated by short tandem repeat (STR) profiling before receipt and were propagated for less than 6 months after resuscitation. These cells were cultured at 37°C under 5% CO2 in Roswell Park Memorial Institute 1640 medium (RPMI-1640; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (ICN, Aurora, OH, USA), and penicillin/streptomycin (Meiji Seika, Tokyo, Japan).
The transgenic vector was transfected using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocol. Stably transfected cells were selected in the DOI: 10.1158 /1078 -0432.CCR-14-1936 presence of 200 µg/mL G418 (Sigma, St Louis, MO, USA) over 30 days. We confirmed the proper transgene insertion by polymerase chain reaction (PCR) and immunocytochemistry.
Immunohistochemistry and immunocytochemistry
Immunohistochemistry and immunocytochemistry were performed as previously reported. (24, 25) Anti-human K19 mouse antibodies (Dako, Glostrup, Denmark) diluted at 1:100, anti-human Ki-67 mouse antibodies (BioLegend, San Diego, USA) diluted at Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 
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The total RNA was extracted with RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA) and RNase-free DNAse (Qiagen). The genomic DNA was extracted with QuickGene-SP Kit (FUJIFILM, Tokyo, Japan). The Omniscript Reverse Transcription Kit (Qiagen) was used according to the manufacturer's protocol to reverse transcribe 1 µg total RNA into cDNA. Primers were generated for the following genes: K19, pEGFP1, CD90, EpCAM, TGFbR1, snail1, slug, E-cadherin, vimentin, multidrug-resistance protein-5 (MRP5), and actin-beta. Their sequences are summarized in Supplemental Table 2 . PCR and RT-PCR assays were performed as previously described. (26) We performed qPCR and qRT-PCR assays using SYBR-green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on the ABI 7500 system (Applied Biosystems). Each target was run in triplicate, and expression levels were normalized to those of actin-beta.
Flow cytometry and single-cell culture analysis
We prepared the cultured cells as described previously. (27, 28) DOI: 10.1158 /1078 -0432.CCR-14-1936 PE-conjugated mouse IgG2b (BioLegend) was used as an isotype control for the PE-conjugated EpCAM antibody. PE-conjugated mouse IgG1 (BioLegend) was used as an isotype control of the PE-conjugated CD90 antibody. The cells were analyzed and isolated using a FACSAria cell sorter (BD Biosciences).
We performed single-cell culture analyses as previously described. (27, 28) The individual isolated cells were each sorted into 96-well culture plates using FACSAria (BD Biosciences). We used a light microscope 10-16h after cell sorting to confirm that each well contained only one cell. Following cell expansion after isolation of each clone, we subjected the cells to flow cytometry.
Cell proliferation assay, anchorage-independent growth assay, and sphere-forming assay We inoculated the isolated EGFP + and EGFP − cells differentiated from one EGFP + cell at a density of 1×10 3 cells per well in 96-well culture plates, which were then allowed to grow for 7 days. The cell numbers were determined using the Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 according to the manufacturer's protocol. After 1 h of incubation, the absorbance value was measured using a plate reader at 490 nm.
To examine the anchorage-independent growth, 1 × 10 4 EGFP + and EGFP − cells were suspended in 2.0 mL of 0.3% agar (Wako) supplemented with culture medium. The cell suspension was layered over the bottom layer of 2.0 mL of 0.6% agar. We counted the colonies 14 days after cell sorting.
To investigate the ability to form cell spheres, 1 × 10 5 EGFP + and EGFP − were seeded in 6-well ultra-low attachment plates (Corning Inc., NY, USA) in serum-free medium. We observed the spheres 5 days after cell sorting. Wound healing assay and migration assay Wound healing assays were used to assess capacity for cell motility. We seeded the isolated EGFP + and EGFP − cells differentiated from one EGFP + cell at a density of 1 × 10 6 cells per well in 35-mm culture dishes. On reaching full confluency, the cell layer was scratched with a 10-µL plastic tip and then cultured with low serum (2% fetal bovine serum) culture medium with or without 0.5 µM LY2157299. Micrographs were taken at 24 or 48 h after the scratch.
For migration assays, 8-µm-pore 24-well cell culture plates (Corning Inc.) coated with type I collagen were used. We plated 2.5 × 10 4 EGFP + and EGFP − cells in the upper chamber with serum-free medium; in the lower chamber, normal culture medium containing 10% fetal bovine serum was added. After 48 h of incubation, the cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed with 4% paraformaldehyde and stained using the Diff-Quick staining kit (Sysmex, Kobe, Japan).
Research. DOI: 10.1158 /1078 -0432.CCR-14-1936 Western blot analysis Western blot analysis was performed as previously reported. (29) Primary antibodies recognizing phospho-smad2 (pSmad2) (Ser465/467, #3108; Cell Signaling, Tokyo, Japan), Smad2 (#5339, Cell Signaling), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc-25778, Santa Cruz Biotechnology Inc., Santa Cruz, CA) were used at 1:1000 dilution.
K19 knockdown with RNA interference
We transfected K19-siRNA (#4427037-s7998 or #4427037-s7999, Invitrogen) or control-siRNA (#4390843, Invitrogen) into HCC cells using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocol. The final concentrations were 10nM. K19 expression was significantly downregulated by both K19 siRNAs (Supplemental Fig. 1D ). According to the same result acquired with both siRNAs, K19-siRNA (#4427037-s7999) was shown as representative data. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 Experiments on a TGFbR1 inhibitor in a mouse xenograft model To investigate the therapeutic effect of the TGFbR1 inhibitor in vivo, we performed experiments using LY2157299 in a mouse xenograft model. Isolated 1 × 10 6 EGFP + or EGFP − cells were injected subcutaneously into the right and left dorsal areas of anesthetized NOD/SCID mice. Thereafter, 24 days after the xenotransplantation, we treated bid with either saline (control group; n = 5) or 75 mg/kg LY2157299 (treated group; n = 5) for 10 consecutive days. Tumor size was measured every 3 days for 36 days after engraftment; afterwards, the animals were sacrificed.
All animal experimental procedures were performed according to the Animal Protection Guidelines of Kyoto University.
Statistical analysis
The statistical analyses were performed using SPSS version 17.0 (SPSS Inc., IL, USA) and GraphPad Prism software version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Student's t-test, F-test, Mann-Whitney U test, Fisher's exact test or chi-squared test, and repeated-measures analyses of variances were used for assessment. The mean ± SD of three or more independent experiments is reported.
Research. DOI: 10.1158 /1078 -0432.CCR-14-1936 Recurrence-free survival (RFS) and overall survival (OS) after the operation were calculated using the Kaplan-Meier method and analyzed with the log-rank test.
Significant variables from the univariate analysis were entered in the multivariate analysis using a Cox regression model with forward stepwise selection. Statistical significance was defined as P < 0.05. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 and EGFP, whereas the sorted EGFP − cells did not express either molecule (Supplemental Fig. 1C) . Additionally, qPCR assays showed that the K19-EGFP reporter vector was almost equally transfected into both EGFP + and EGFP − cells (Supplemental Fig. 1C ). These results indicated that the EGFP + cells corresponded to the K19 + cells and that cell sorting could divide the Huh7, PLC/PRF/5, and Hep3B cells according to their K19 production. Therefore, we performed further investigations of the K19 + cells in Huh7, PLC/PRF/5, and Hep3B cells to determine whether they were cancer stem cells.
Single-cell culture analysis
We performed single-cell culture analyses to examine self-renewal activity and multipotency. Notably, single K19 + Huh7 cells generated both K19 + and K19 − cell fractions, although single K19 − Huh7 cells produced only a K19 − cell fraction (Fig. 1A) .
These findings were reproducible in three trials (three EGFP + /EGFP − clones). Similar results were obtained with PLC/PRF/5 and Hep3B cells (Supplemental Fig. 2A DOI: 10.1158 /1078 -0432.CCR-14-1936 Cell proliferation assay, anchorage-independent growth assay, and sphere-forming assay Compared to the K19 − Huh7 cells, K19 + Huh7 cells showed higher proliferation activity (P < 0.01, n = 3; Fig. 1B ) and exhibited a higher ability to form colonies in soft agar (P < 0.05, n = 3; Fig. 1C ). In addition, the sphere assays revealed that K19 + Huh7 cells formed cell spheres 5 days after cell sorting, whereas the K19 − Huh7 cells did not ( DOI: 10.1158 /1078 -0432.CCR-14-1936 To investigate the mechanism responsible for 5-FU resistance, we analyzed the mRNA expressions of multidrug-resistance protein-5 (MRP5), a key drug transporter for Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assays of the three cell lines showed that the MRP5 expression of K19 + cells was three or more fold higher than that of K19 − cells (Fig. 1D, Supplemental Fig. 2D , P < 0.05).
Xenotransplantation into immunodeficient mice
To explore cancer stem cell properties in vivo, we transplanted 1 × 10 4 K19 + or K19 − cells derived from one K19 + cell into the backs of NOD/SCID mice. K19 + Huh7 cells produced larger, hypervascular tumors in 10/10 mice, whereas K19 − Huh7 cells produced smaller, pale-looking tumors in 4/10 mice ( Fig. 2A, 2B ). FACS analyses and immunohistological assays revealed that the tumors from K19 + cells had both K19 + and K19 − cell fractions, whereas the tumors from K19 − cells had only K19 − cell fractions (Fig.   2C, 2D) . In serial transplantation, we transplanted 1.0 × 10 4 K19 + or K19 − cells isolated from tumors produced by K19 + cells. The tumors derived from K19 + cells also contained K19 + and K19 − cell fractions. In contrast, the tumors derived from K19 − cells consisted of only K19 − cell fractions (Fig. 2D) . Similar results were obtained with PLC/PRF/5 and Hep3B cells (Supplemental Fig. 3A−D DOI: 10.1158 /1078 -0432.CCR-14-1936 possess the capacity to replicate themselves, to generate heterogeneous lineages of cancer cells, and to initiate tumors in vivo.
Relationship between K19 and reported HCC-CSCs markers
In the three cell lines that expressed K19, EpCAM expression was observed in Huh7 and Hep3B cells, whereas CD90 expression was observed in HLF and PLC/PRF/5 cells (Fig. 3A) . qRT-PCR assays demonstrated significantly higher expression of EpCAM in K19 + Huh7 and Hep3B cells than in K19 − cells (P < 0.05, Fig. 3B ). K19 + PLC/PRF/5 cells showed higher CD90 expression than K19 − cells, although the difference was not statistically significant (P = 0.061, Fig. 3B ). In FACS analyses, the proportion of EpCAM + cells in K19 + Huh7/Hep3B cells tended to be larger than that in K19 − cells (Fig.   3C ). Only a few CD90 + cells were seen in K19 + PLC/PRF/5 cells or in K19 − PLCPRF/5 cells (Fig. 3C) .
We further explored the growth potential of K19 + EpCAM + , K19 − EpCAM + , and K19 − EpCAM − cells. Cell proliferation assays indicated that K19 + EpCAM + Huh7/Hep3B cells had greater proliferation capability than K19 − EpCAM + cells (P < 0.01, Fig. 3D ).
K19 − EpCAM + cells showed slightly faster growth than K19 − EpCAM − cells, although the difference was not statistically significant (Huh7, P = 0.39; Hep3B, P = 0.75; Fig. 3D ).
Research. DOI: 10.1158 /1078 -0432.CCR-14-1936 These data suggest that the pattern of K19 expression in K19 + HCC cells may be similar to that of EpCAM, and that K19 may play a stronger role than EpCAM in the proliferative capacity of HCC-CSCs.
Involvement of K19 expression in EMT and TGFb/Smad signaling
To investigate the involvement of K19 in EMT and TGFb/Smad signaling, we evaluated the expression pattern of EMT-related markers in HCC cell lines (Fig. 4A) . qRT-PCR assays revealed that K19 + Huh7 cells showed an EMT gene expression profile:
down-regulation of E-cadherin and up-regulation of TGFbR1, snail1, slug, and vimentin (P < 0.05, Fig. 4A ). Wound healing and migration assays revealed that K19 + cells possessed significantly greater motility than K19 − cells (Fig. 4A ). This high motility of K19 + cells was suppressed by K19 knockdown via RNA interference (Supplemental Fig.   1D ). These data indicate that K19 + HCC cells have a strong association with EMT.
With the primary focus on strong TGFbR1 expression of K19 + cells, we explored TGFb/Smad signaling in K19 + cells. Western blot analysis of pSmad2/Smad2 showed that K19 + Huh7 cells expressed pSmad2 more strongly than did K19-cells (Fig. 4B) . (Fig. 4C) .
Notably, in these experiments, K19 + tumors treated with LY2157299 were significantly smaller than K19 + tumors treated with saline, whereas LY2157299 showed no significant effectiveness against K19 − tumors (K19 + , P < 0.01; K19 − , n.s.; not significant, (Fig. 5A ). K19 expression was detected in a large proportion or small proportion of HCC tissues (Fig. 5A ). In the resection group, the median recurrence-free survival (RFS) and overall survival (OS) were, respectively, 417 and 1099 days for K19 + patients, and 1038 and 1857 days for K19 − patients (Fig. 5B ). In the transplantation group, the median RFS and OS were, respectively, 1616 and 1700 days for K19 + patients, and 2740 and 2657 days for K19 − patients (Fig. 5B) . In both groups, K19 + patients had significantly lower RFS (resection group, P < 0.001; transplantation group, P = 0.001) and OS (resection group, P = 0.002; transplantation group, P = 0.016).
In the resection group, the log-rank test revealed that K19 expression, preoperative low albumin concentration, portal vein invasion, and liver cirrhosis were associated Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 with worsened RFS (Supplemental Table 3 ). Multivariate analysis demonstrated that K19 expression and portal vein invasion were independent predictors of postoperative recurrence (Table 1 ). K19 expression, low albumin concentration, portal vein invasion, and liver cirrhosis were associated with OS by log-rank test (Supplemental Table 3 ).
Multivariate analysis showed that low albumin concentration, portal vein invasion and liver cirrhosis were independent predictors of OS, whereas K19 expression was not (Table 1 ). In the transplantation group, K19 expression, tumor differentiation, and portal invasion significantly decreased both RFS and OS (Supplemental Table 4 ).
Multivariate analysis revealed that K19 expression predicted postoperative recurrence (Table 1) . Regarding OS, K19 expression and portal vein invasion were independent predictors of postoperative survival in multivariate analysis (Table 1) . Additionally, K19 expression tended to relate to tumor size in the resection (Fig. 5C , P = 0.086) and transplantation groups ( Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 K19 − patients in the resection group, and in 5/7 (71%) K19 + and 15/55 (27%) K19 − patients in the transplantation group. In K19 + TGFbR1 + patients, TGFbR1 expression was detected in K19 + and K19 − HCC cells (Fig. 5D ). Many K19 + TGFbR1 + cells were seen in the invasive front of HCC (Fig. 5D, upper panel) . In both groups, K19 expression was significantly correlated with TGFbR1 expression (resection group, P < 0.01; transplantation group, P = 0.019). DOI: 10.1158 /1078 -0432.CCR-14-1936 K19 + cells could self-renew, differentiate into K19 − cells, and generate larger tumors with a higher incidence in vivo. These findings strongly suggest that K19 + cells in HCC possess CSC characteristics.
Immunohistochemical analyses of 166 patients revealed that K19 expression was an independent predictor of postoperative recurrence in both resection and transplantation patients, and it was also an independent predictor for OS in the transplantation group. However, in the resection group, K19 expression tended to relate to poor postoperative survival although the difference was not statistically significant (P = 0.088). This result may be attributed to the fact that patients in the resection group have more HCC treatment choices than those in the transplantation group after HCC recurrence, e.g., RFA, transarterial chemoembolization, and systemic chemotherapy. DOI: 10.1158 /1078 -0432.CCR-14-1936 in FACS analyses. Similar to recent studies reporting that EpCAM was associated with tumor size.(31) our xenotransplantation assays revealed that K19 + cells generated larger tumors. Moreover, a proliferation assay of K19 + EPCAM + , K19 − EpCAM + , and K19 − EpCAM − cells suggested that K19 may be more strongly associated with rapid tumor growth than EpCAM.
We found that TGFb/Smad signaling was activated in K19 + cells and suppressed by K19 knockdown. Moreover, K19 knockdown also suppressed the aggressiveness of K19 + cells. These results indicate that TGFb/Smad signaling is involved in conferring the high proliferation ability to K19 + cells. K19 has been reported by Govaere et al (22) as a key player in HCC invasion. They reported that K19-positive HCCs highly express invasion or metastasis-related markers. (22) Our results also showed a close correlation between K19 and the EMT which is known as a major mediator of tumor migration/invasion. During EMT, cancer cells shed their epithelial characteristics and acquire more migratory mesenchymal cell-like properties. In this study, we confirmed that K19 + cells express several genes associated with EMT and have higher motility and migration than K19 − cells. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 because we could then identify K19 + patients without immunohistochemistry or RT-PCR analysis of HCC tissues.
In conclusion, our study indicates that K19 + HCC cells possess CSC properties, are closely associated with TGFb/Smad signaling and EMT, and would be sensitive to a TGFbR1 inhibitor. We believe that further studies of K19-related mechanisms will provide novel therapeutic approaches in HCC treatment. Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 DOI: 10.1158 /1078 -0432.CCR-14-1936 K19 expression 18.4 (1.97-171.3) 0.01 DOI: 10.1158 /1078 -0432.CCR-14-1936 Figure legends Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 as the mean ± SD (K19 + Huh7: n = 10, K19 -Huh7: n = 4). Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 Tumors produced by K19 + and K19 − Huh7 cells and sequential tumor size with LY2157299 or control treatment in NOD/SCID mice (repeated-measures ANOVA, K19 + , P < 0.01; K19 − , n.s.; not significant). Data are shown as the mean ± SD (n = 5). Ki-67 staining of tumors and Ki-67 positive cell numbers (lower panel, Student's t-test, K19 + , P < 0.01; K19 − , n.s.; not significant). Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-14-1936 DOI: 10.1158 /1078 -0432.CCR-14-1936 
